KASID
Search
- Page Path
- HOME > Search
Original Articles
- Efficacy and safety of etrasimod in Japanese patients with ulcerative colitis: results from a phase 2 dose-ranging study
- Ken Takeuchi, Hiroshi Nakase, Tadakazu Hisamatsu, Katsuyoshi Matsuoka, Shoko Arai, Hirotoshi Yuasa, Motoki Oe, Ryosuke Ono, Michael Keating, Guibao Gu, Krisztina Lazin, Aoibhinn McDonnell, Koki Fukuta, Toshifumi Hibi
- Received December 17, 2024 Accepted March 4, 2025 Published online April 25, 2025
- DOI: https://doi.org/10.5217/ir.2024.00213 [Epub ahead of print]
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Background/Aims
Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). However, its efficacy, safety, and the appropriate dosage have not been extensively investigated in the Japanese population.
Methods
This phase 2, multicenter, randomized, double-blind, placebo-controlled dose-ranging, 12-week trial was carried out among Japanese patients with moderately to severely active UC. Patients were randomized 1:1:1 to receive etrasimod 1 mg once daily (QD), etrasimod 2 mg QD, or placebo. The primary efficacy endpoint was the proportion of patients achieving clinical remission at week 12. Secondary efficacy endpoints and treatmentemergent adverse events (TEAEs) were also investigated. Efficacy endpoints were presented as proportions of patients achieving each outcome.
Results
Overall, 17, 19, and 18 patients received etrasimod 1 mg QD, etrasimod 2 mg QD, and placebo, respectively. One patient receiving etrasimod 1 mg (6.7%), 5 patients receiving etrasimod 2 mg (26.3%), and no patients receiving placebo (0%) achieved clinical remission. More patients receiving etrasimod versus placebo achieved secondary endpoints, except endoscopic normalization, at week 12. TEAEs were experienced by 9 patients receiving etrasimod 1 mg (52.9%), 13 patients receiving etrasimod 2 mg (68.4%), and 10 patients receiving placebo (55.6%). None of the TEAEs were serious and none experienced by patients receiving etrasimod led to treatment discontinuation.
Conclusions
Overall, etrasimod 2 mg QD for up to 12 weeks appeared efficacious and safe in these Japanese patients with moderately to severely active UC. All TEAEs were mild to moderate in severity. (ClinicalTrials.gov: NCT05061446)
- 898 View
- 158 Download
- IBD
- Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study
- Shiro Nakamura, Hirotsugu Imaeda, Hiroki Nishikawa, Masaki Iimuro, Minoru Matsuura, Hideo Oka, Junsuke Oku, Takako Miyazaki, Hirohito Honda, Kenji Watanabe, Hiroshi Nakase, Akira Andoh
- Intest Res 2018;16(4):554-562. Published online October 10, 2018
- DOI: https://doi.org/10.5217/ir.2018.00027
-
Abstract
PDFPubReaderePub
- Background/Aims
Noninvasive objective monitoring is advantageous for optimizing treatment strategies in patients inflammatory bowel disease (IBD). Fecal calprotectin (FCP) is superior to traditional biomarkers in terms of assessing the activity in patients with IBD. However, there are the differences among several FCP assays in the dynamics of FCP. In this prospective multicenter trial, we investigated the usefulness of fecal FCP measurements in adult Japanese patients with IBD by reliable enzyme immunoassay using a monoclonal antibody.
Methods
We assessed the relationship between FCP levels and disease or endoscopic activity in patients with ulcerative colitis (UC, n=64) or Crohn’s disease (CD, n=46) compared with healthy controls (HCs, n=64).
Results
FCP levels in UC patients strongly correlated with the Disease Activity Index (rs=0.676, P<0.0001) and Mayo endoscopic subscore (MES; rs=0.677, P<0.0001). FCP levels were significantly higher even in patients with inactive UC or CD compared with HCs (P=0.0068, P<0.0001). The optimal cutoff value between MES 1 and 2 exhibited higher sensitivity (94.1%). FCP levels were significantly higher in active UC patients than in inactive patients (P<0.001), except those with proctitis. The Crohn’s Disease Activity Index tended to correlate with the FCP level (rs=0.283, P=0.0565).
Conclusions
Our testing method using a monoclonal antibody for FCP was well-validated and differentiated IBD patients from HCs. FCP may be a useful biomarker for objective assessment of disease activity in adult Japanese IBD patients, especially those with UC. -
Citations
Citations to this article as recorded by
- Combining mechanistic modeling with machine learning as a strategy to predict inflammatory bowel disease clinical scores
Jaehee V. Shim, Markus Rehberg, Britta Wagenhuber, Piet H. van der Graaf, Douglas W. Chung
Frontiers in Pharmacology.2025;[Epub] CrossRef - Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021
Hiroshi Nakase, Motohiro Esaki, Fumihito Hirai, Taku Kobayashi, Katsuyoshi Matsuoka, Minoru Matsuura, Makoto Naganuma, Masayuki Saruta, Kiichiro Tsuchiya, Motoi Uchino, Kenji Watanabe, Tadakazu Hisamatsu, Akira Andoh, Shigeki Bamba, Motohiro Esaki, Mikihi
Journal of Gastroenterology.2023; 58(4): 313. CrossRef - Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine
Tomohiro Fukuda, Makoto Naganuma, Kaoru Takabayashi, Yuya Hagihara, Shun Tanemoto, Ena Nomura, Yusuke Yoshimatsu, Shinya Sugimoto, Kosaku Nanki, Shinta Mizuno, Yohei Mikami, Kayoko Fukuhara, Tomohisa Sujino, Makoto Mutaguchi, Nagamu Inoue, Haruhiko Ogata,
Journal of Gastroenterology and Hepatology.2020; 35(11): 1878. CrossRef - Clinical management for small bowel of Crohn’s disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion
Kenji Watanabe
Intestinal Research.2020; 18(4): 347. CrossRef
- Combining mechanistic modeling with machine learning as a strategy to predict inflammatory bowel disease clinical scores
- 7,903 View
- 180 Download
- 5 Web of Science
- 4 Crossref
Brief Communication
- IBD
- Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
- Tadakazu Hisamatsu, Reiko Kunisaki, Shiro Nakamura, Tomoyuki Tsujikawa, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Kaoru Yokoyama, Masakazu Nagahori, Takanori Kanai, Makoto Naganuma, Hirofumi Michimae, Akira Andoh, Akihiro Yamada, Tadashi Yokoyama, Noriko Kamata, Shinji Tanaka, Yasuo Suzuki, Toshifumi Hibi, Mamoru Watanabe
- Intest Res 2018;16(3):494-498. Published online July 27, 2018
- DOI: https://doi.org/10.5217/ir.2018.16.3.494
-
PDFSupplementary MaterialPubReaderePub
-
Citations
Citations to this article as recorded by- Partial Enteral Nutrition in the Management of Crohn’s Disease: A Systematic Review and Meta-Analysis
Aleksandra Jatkowska, Bernadette White, Konstantinos Gkikas, John Paul Seenan, Jonathan MacDonald, Konstantinos Gerasimidis
Journal of Crohn's and Colitis.2025;[Epub] CrossRef - Patient experiences with and adherence to Crohn’s disease exclusion diet in Dutch Crohn’s disease patients: a cohort study
Fleur T. R. Wijers, Suzanne M. C. van Zundert, Charlotte M. Verburgt, Nikki van der Kruk, Johan E. Van Limbergen, Nicolette J. Wierdsma
Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef - Nutrition and dietary therapy in paediatric inflammatory bowel disease
Konstantinos Gerasimidis
Clinical Nutrition ESPEN.2025; 67: 233. CrossRef - Pancreatic Enzyme Replacement Therapy Improves Exclusive Enteral Nutrition Related Diarrhea in Crohn's Disease: A Prospective Randomized Trial
Jian Kang, Jing Wang, Juan Su, Wei Wang, Yueyue Lu, Zhishun Tang, Liping Zou, Anning Yin, Jiao Li, Haixia Ren, Qian Zhou, Huipeng Wan, Ping An
United European Gastroenterology Journal.2025;[Epub] CrossRef - Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn’s disease
Sisi Zhou, Zeyu Huang, Wenjing Hou, Yiting Lin, Jing Yu
Inflammation Research.2024; 73(2): 199. CrossRef - Role of diet in prevention versus treatment of Crohn’s disease and ulcerative colitis
Emma P Halmos, Lihi Godny, Julie Vanderstappen, Chen Sarbagili-Shabat, Vaios Svolos
Frontline Gastroenterology.2024; : flgastro-2023-102417. CrossRef - Immunoregulatory Effects of Elemental Diet and Its Ingredient, Tryptophan, via Activation of the Aryl Hydrocarbon Receptor in Mice
Atsuhito Kubota, Shungo Imai, Ryoichi Aoyagi, Wataru Murase, Masaru Terasaki, Mitsuru Sugawara, Yoh Takekuma, Hiroyuki Kojima
International Journal of Molecular Sciences.2024; 25(6): 3448. CrossRef - Real-world evidence of combined treatment of biologics and exclusive enteral nutrition in patients with ileum-dominant Crohn's disease: A multicenter study
Wei Wang, Anning Yin, Jing Wang, Jiao Li, Jingyun Cheng, Jian Kang, Yaqing Xu, Yueyue Lu, Yuanping Yang, Juan Su, Qian Zhou, Ya Liu, Zhishun Tang, Haixia Ren, Weiwei Li, Weiguo Dong, Baoping Yu, Ping An
Clinical Nutrition.2024; 43(6): 1291. CrossRef - It’s Time to Change Tack in IBD Treatment
Marcel A. Behr, Ildiko Mehes, Charles N. Bernstein
Gastroenterology.2024; 167(6): 1065. CrossRef - "Out of the box� new therapeutic strategies for Crohn�s disease: moving beyond biologics
Ignacio Catalán-Serra, Pret Ricanek, Tore Grimstad
Revista Española de Enfermedades Digestivas.2022;[Epub] CrossRef - Nutritional Therapy Strategies in Pediatric Crohn’s Disease
Charlotte M. Verburgt, Mohammed Ghiboub, Marc A. Benninga, Wouter J. de Jonge, Johan E. Van Limbergen
Nutrients.2021; 13(1): 212. CrossRef - Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu I
Journal of Gastroenterology.2021; 56(6): 489. CrossRef - Diet and nutrition in the management of inflammatory bowel disease
Pabitra Sahu, Saurabh Kedia, Vineet Ahuja, Rakesh K. Tandon
Indian Journal of Gastroenterology.2021; 40(3): 253. CrossRef - Nutritional Aspects of Pediatric Gastrointestinal Diseases
Teresa Di Chio, Christiane Sokollik, Diego G. Peroni, Lara Hart, Giacomo Simonetti, Franziska Righini-Grunder, Osvaldo Borrelli
Nutrients.2021; 13(6): 2109. CrossRef - Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
Sanchit Sharma, Arti Gupta, Saurabh Kedia, Samagra Agarwal, Namrata Singh, Sandeep Goyal, Saransh Jain, Vipin Gupta, Pabitra Sahu, Sudheer Kumar Vuyyuru, Bhaskar Kante, Raju Sharma, Rajesh Panwar, Peush Sahni, Govind Makharia, Vineet Ahuja
Intestinal Research.2021; 19(3): 291. CrossRef - Nutritional Therapies and Their Influence on the Intestinal Microbiome in Pediatric Inflammatory Bowel Disease
Lara Hart, Charlotte M. Verburgt, Eytan Wine, Mary Zachos, Alisha Poppen, Mallory Chavannes, Johan Van Limbergen, Nikhil Pai
Nutrients.2021; 14(1): 4. CrossRef - Efficacy of enteral nutrition in patients with Crohn’s disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis
Fumihito Hirai, Teruyuki Takeda, Yasumichi Takada, Masahiro Kishi, Tsuyoshi Beppu, Noritaka Takatsu, Masaki Miyaoka, Takashi Hisabe, Kenshi Yao, Tosiharu Ueki
Journal of Gastroenterology.2020; 55(2): 133. CrossRef - Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns?-
Shinji Okabayashi, Taku Kobayashi, Toshifumi Hibi
Journal of the Anus, Rectum and Colon.2020; 4(1): 1. CrossRef - Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience
Ajit Sood, Arshdeep Singh, Ritu Sudhakar, Vandana Midha, Ramit Mahajan, Varun Mehta, Yogesh Kumar Gupta, Kirandeep Kaur
Intestinal Research.2020; 18(2): 184. CrossRef - Enteral nutrition in the biologic era: learn from yesterday, live for today, hope for tomorrow
Tadakazu Hisamatsu
Intestinal Research.2020; 18(2): 139. CrossRef - Half-Elemental Diet Shifts the Human Intestinal Bacterial Compositions and Metabolites: A Pilot Study with Healthy Individuals
Jun Miyoshi, Daisuke Saito, Mio Nakamura, Miki Miura, Tatsuya Mitsui, Toru Kudo, Shinnosuke Murakami, Minoru Matsuura, Tadakazu Hisamatsu
Gastroenterology Research and Practice.2020; 2020: 1. CrossRef - Fool me once… treatment exposure to achieve remission in pediatric IBD
Johan E. Van Limbergen, Bart G. P. Koot, J. Peter de Winter
European Journal of Pediatrics.2020; 179(12): 1921. CrossRef - Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease
Esteban Sáez-González, Beatriz Mateos, Pedro López-Muñoz, Marisa Iborra, Inés Moret, Pilar Nos, Belén Beltrán
Nutrients.2019; 11(5): 1062. CrossRef
- Partial Enteral Nutrition in the Management of Crohn’s Disease: A Systematic Review and Meta-Analysis
- 7,698 View
- 158 Download
- 22 Web of Science
- 23 Crossref
Statement
- IBD
- Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
- Taku Kobayashi, Tadakazu Hisamatsu, Yasuo Suzuki, Haruhiko Ogata, Akira Andoh, Toshimitsu Araki, Ryota Hokari, Hideki Iijima, Hiroki Ikeuchi, Yoh Ishiguro, Shingo Kato, Reiko Kunisaki, Takayuki Matsumoto, Satoshi Motoya, Masakazu Nagahori, Shiro Nakamura, Hiroshi Nakase, Tomoyuki Tsujikawa, Makoto Sasaki, Kaoru Yokoyama, Naoki Yoshimura, Kenji Watanabe, Miiko Katafuchi, Mamoru Watanabe, Toshifumi Hibi
- Intest Res 2018;16(2):168-177. Published online April 30, 2018
- DOI: https://doi.org/10.5217/ir.2018.16.2.168
-
Abstract
PDFPubReaderePub
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.
-
Citations
Citations to this article as recorded by- Precision medicine in inflammatory bowel diseases
Ashwin N. Ananthakrishnan
Intestinal Research.2024; 22(1): 8. CrossRef - Impact of Concomitant Prescriptions and Lifestyle Factors on the Initial Course of Newly Diagnosed Inflammatory Bowel Disease
Hiromu Morikubo, Takayoshi Nagahama, Katsuhiko Nagai, Hajime Yamazaki, Taku Kobayashi
Inflammatory Intestinal Diseases.2024; 9(1): 260. CrossRef - A Retrospective Cohort Study of Clinical Features and Treatment Patterns With Ustekinumab in Patients With Crohn Disease Utilizing a Health Care Database in Japan
Yanfang Liu, Choo Hua Goh, Hong Qiu, Kuan-Chih Huang, Hsingwen Chung, Carine Saadoun
Annals of Pharmacotherapy.2023; 57(9): 1053. CrossRef - Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis
Kunio Asonuma, Taku Kobayashi, Masaru Nakano, Shintaro Sagami, Hiroki Kiyohara, Mao Matsubayashi, Hiromu Morikubo, Yusuke Miyatani, Shinji Okabayashi, Hajime Yamazaki, Yuichiro Kuroki, Toshifumi Hibi
Inflammatory Bowel Diseases.2022; 28(2): 200. CrossRef - Intestinal cancer in patients with Crohn's disease: A systematic review and meta‐analysis
Motoi Uchino, Hiroki Ikeuchi, Keisuke Hata, Tomohiro Minagawa, Yuki Horio, Ryuichi Kuwahara, Shiro Nakamura, Kenji Watanabe, Masayuki Saruta, Toshimitsu Fujii, Taku Kobayashi, Ken Sugimoto, Fumihito Hirai, Motohiro Esaki, Sakiko Hiraoka, Katsuyoshi Matsuo
Journal of Gastroenterology and Hepatology.2021; 36(2): 329. CrossRef - MR-enterography in Crohn’s disease: what MRE mural parameters are associated to one-year therapeutic management outcome?
Pier Paolo Mainenti, Fabiana Castiglione, Antonio Rispo, Ettore Laccetti, Salvatore Guarino, Valeria Romeo, Anna Testa, Leonardo Pace, Simone Maurea
The British Journal of Radiology.2021;[Epub] CrossRef - Incidence and Outcomes of Perianal Disease in an Asian Population with Crohn’s Disease: A Nationwide Population-Based Study
Eun Mi Song, Ho-Su Lee, Ye-Jee Kim, Eun Hye Oh, Nam Seok Ham, Jeongseok Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Jong Lyul Lee, Yong Sik Yoon, Chang Sik Yu, Suk-Kyun Yang
Digestive Diseases and Sciences.2020; 65(4): 1189. CrossRef - Passion fruit (Passiflora edulis) leaf aqueous extract ameliorates intestinal epithelial barrier dysfunction and reverts inflammatory parameters in Caco-2 cells monolayer
Mônica Cristina Lopes do Carmo, Isabela Mateus Martins, Ana Elisa Ramos Magalhães, Mário Roberto Maróstica Júnior, Juliana Alves Macedo
Food Research International.2020; 133: 109162. CrossRef - Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
Toshifumi Hibi, Satoshi Motoya, Toshifumi Ashida, Souken Sai, Yukinori Sameshima, Shiro Nakamura, Atsuo Maemoto, Masahiro Nii, Barbara A Sullivan, Robert A. Gasser Jr, Yasuo Suzuki
Intestinal Research.2019; 17(3): 375. CrossRef
- Precision medicine in inflammatory bowel diseases
- 7,824 View
- 137 Download
- 8 Web of Science
- 9 Crossref
Letters to the Editor
- Author's Reply
- Tomoya Iida, Hiroyuki Kaneto, Hiroshi Nakase
- Intest Res 2017;15(4):554-554. Published online October 23, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.4.554
- 5,592 View
- 40 Download
Original Articles
- Clinical outcomes of sigmoid colon volvulus: identification of the factors associated with successful endoscopic detorsion
- Tomoya Iida, Suguru Nakagaki, Shuji Satoh, Haruo Shimizu, Hiroyuki Kaneto, Hiroshi Nakase
- Intest Res 2017;15(2):215-220. Published online April 27, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.2.215
-
Abstract
PDFPubReaderePub
<b>Background/Aims</b><br/> Although multiple treatment options exist for the management of sigmoid colon volvulus, no study has examined the factors associated with successful endoscopic detorsion. This study aimed to examine the clinical course of patients with sigmoid colon volvulus and to identify factors related to successful endoscopic detorsion.
Methods This study included 30 cases (21 patients) of sigmoid volvulus from among 545 cases of intestinal obstruction at a single center. We retrospectively examined the clinical course and the factors associated with the possibility of endoscopic detorsion of sigmoid colon volvulus.
Results The rate of laxative use among the study participants was 76.2%; the rate of comorbid neuropsychiatric disorders was 61.9%; and 57.1% of patients had a history of open abdominal surgery. All patients were initially treated with endoscopic detorsion, and this procedure had a 61.9% success rate. The recurrence rate after detorsion was as high as 46.2%, but detorsion during revision endoscopy was possible in all cases. Statistical analysis revealed that the absence of abdominal tenderness (
P =0.027), the use of laxatives (P =0.027), and a history of open abdominal surgery (P =0.032) were factors predictive of successful endoscopic detorsion.Conclusions The results of our study are consistent with previous reports with respect to the success rate of endoscopic detorsion, the subsequent recurrence rate, and the proportion of patients requiring surgical treatment. In addition, we identified the absence of abdominal tenderness, the use of laxatives, and history of open abdominal surgery as factors predicting successful endoscopic detorsion of sigmoid colon volvulus.
-
Citations
Citations to this article as recorded by- Evaluating Racial Disparities in 30-day Outcomes for African Americans Following Colectomy for Volvulus
Renxi Li, Susan Kartiko
The American Surgeon™.2025; 91(2): 266. CrossRef - Effect of the timing of endoscopic detorsion on clinical outcomes in patients with sigmoid volvulus
Refael Aminov, Anton Bermont, Vered Richter, Haim Shirin, Daniel L. Cohen
Gastrointestinal Endoscopy.2025;[Epub] CrossRef - Should we adopt a “laparoscopy first” strategy? A comparison of 30-day outcomes between converted open from laparoscopic and planned open colectomy for volvulus
Renxi Li
Updates in Surgery.2025;[Epub] CrossRef - Clinical outcome of patients treated with endoscopic decompression after failure of detorsion for uncomplicated sigmoid volvulus
Dai Nakamatsu, Tsutomu Nishida, Aya Sugimoto, Kengo Matsumoto, Masashi Yamamoto
DEN Open.2024;[Epub] CrossRef - Comments on “Percutaneous Endoscopic Sigmoidopexy: Still a Way to Go”
Sabri Selcuk Atamanalp
GE - Portuguese Journal of Gastroenterology.2024; 31(3): 151. CrossRef - Dependent functional status is an independent risk factor for 30-day mortality and morbidities following colectomy for volvulus: An ACS-NSQIP study from the United States
Renxi Li
Clinics and Research in Hepatology and Gastroenterology.2024; 48(7): 102391. CrossRef - Sigmoid volvulus as a rare cause of intestinal obstruction in the pediatric population: case series and literature review
Isabel C. Brito Rojas, Mayra A. Hernández Peñuela, Vanessa Medina Gaviria, Martin La Rotta, John M. Escobar Echeverri
International Journal of Surgery Open.2024; 62(2): 149. CrossRef - Transanal Decompression Tube Placement for Treatment of Sigmoid Volvulus
Sakurako Hattori, Osamu Aramaki, Yoshihiro Watanabe, Tomohisa Kamo, Tadashi Furihata, Takafumi Ushiku, Ryuugaku Kaneshiro, Yuichi Kasakura, Isao Murayama, Hiroharu Yamashita, Yukiyasu Okamura
Journal of the Anus, Rectum and Colon.2024; 8(4): 305. CrossRef - Endoscopic Decompression of Sigmoid Volvulus: Review of 748 Patients
Sabri Selcuk Atamanalp
Journal of Laparoendoscopic & Advanced Surgical Techniques.2022; 32(7): 763. CrossRef - Initial Computed Tomography Findings of Long and Distended Colon Are Risk Factors for the Recurrence of Sigmoid Volvulus
Ryusaku Kusunoki, Hirofumi Fujishiro, Tatsuya Miyake, Shinsuke Suemitsu, Masatoshi Kataoka, Aya Fujiwara, Kosuke Tsukano, Satoshi Kotani, Satoshi Yamanouchi, Masahito Aimi, Masaki Tanaka, Youichi Miyaoka, Naruaki Kohge, Tomonori Imaoka, Kouji Yuasa, Kouji
Digestive Diseases and Sciences.2021; 66(4): 1162. CrossRef - Risk factors affecting failure of colonoscopic detorsion for sigmoid colon volvulus: a single center experience
Ahmet Surek, Cevher Akarsu, Eyup Gemici, Sina Ferahman, Ahmet Cem Dural, Mehmet Abdussamet Bozkurt, Turgut Donmez, Mehmet Karabulut, Halil Alis
International Journal of Colorectal Disease.2021; 36(6): 1221. CrossRef - The Association of Coloproctology of Great Britain and Ireland consensus guidelines in emergency colorectal surgery
Andrew S. Miller, Kathryn Boyce, Benjamin Box, Matthew D. Clarke, Sarah E. Duff, Niamh M. Foley, Richard J. Guy, Lisa H. Massey, George Ramsay, Dominic A. J. Slade, James A. Stephenson, Phil J. Tozer, Danette Wright
Colorectal Disease.2021; 23(2): 476. CrossRef - Endoscopic Detorsion for Early Postoperative Roux Limb Torsion after Laparoscopic Gastrectomy: A Case Report and Literature Review
Nobuyuki Sakurazawa, Hiroki Arai, Tomohiko Yasuda, Komei Kuge, Shou Kuriyama, Hideyuki Suzuki, Hiroshi Yoshida
Journal of Nippon Medical School.2021; 88(6): 544. CrossRef - Perioperative Outcomes and Predictors of Mortality After Surgery for Sigmoid Volvulus
Anthony Easterday, Sarah Aurit, Rebecca Driessen, Austin Person, Devi Mukkai Krishnamurty
Journal of Surgical Research.2020; 245: 119. CrossRef - American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the management of acute colonic pseudo-obstruction and colonic volvulus
Mariam Naveed, Laith H. Jamil, Larissa L. Fujii-Lau, Mohammad Al-Haddad, James L. Buxbaum, Douglas S. Fishman, Terry L. Jue, Joanna K. Law, Jeffrey K. Lee, Bashar J. Qumseya, Mandeep S. Sawhney, Nirav Thosani, Andrew C. Storm, Audrey H. Calderwood, Mouen
Gastrointestinal Endoscopy.2020; 91(2): 228. CrossRef - Endoscopic Decompression of Recurrent Sigmoid Volvulus in Pregnancy
Nathaly Cortez, Manuel Berzosa, Kiranmayi Muddasani, Kfir Ben-David
Journal of Investigative Medicine High Impact Case Reports.2020;[Epub] CrossRef - Endoscopic Management of Sigmoid Volvulus in a Debilitated Population: What Relevance?
Manuel Coelho da Rocha, Tiago Capela, Mário Jorge Silva, Gonçalo Ramos, João Coimbra
GE - Portuguese Journal of Gastroenterology.2020; 27(3): 160. CrossRef - Author's Reply
Tomoya Iida, Hiroyuki Kaneto, Hiroshi Nakase
Intestinal Research.2017; 15(4): 554. CrossRef - Comments on clinical outcomes of sigmoid colon volvulus: identification of the factors associated with successful endoscopic detorsion
Sabri Selcuk Atamanalp
Intestinal Research.2017; 15(4): 552. CrossRef
- Evaluating Racial Disparities in 30-day Outcomes for African Americans Following Colectomy for Volvulus
- 7,816 View
- 104 Download
- 24 Web of Science
- 19 Crossref
- Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases
- Naoki Minami, Minoru Matsuura, Yorimitsu Koshikawa, Satoshi Yamada, Yusuke Honzawa, Shuji Yamamoto, Hiroshi Nakase
- Intest Res 2017;15(1):90-96. Published online January 31, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.1.90
-
Abstract
PDFPubReaderePub
<b>Background/Aims</b><br/> Our physicians work to expand the possibilities to treat female patients with inflammatory bowel disease (IBD) who wish to become pregnant. Although many drugs, including 5-aminosalicylate (5-ASA), corticosteroids, immunomodulators, and biologics, are used safely during pregnancy, few reports have described the therapeutic regimen throughout pregnancy and the management of patients who relapse during pregnancy precisely. The aim of this study was to assess the management of patients with IBD during pregnancy.
Methods We identified 19 patients (five with Crohn's disease and 14 with ulcerative colitis [UC]) who became pregnant with a total of 23 pregnancies between May 2005 and May 2015 by reviewing the medical records of Kyoto University Hospital. The following data were collected: the maternal variables, the IBD treatment type, the disease activity, the pregnancy outcome, and the mode of delivery.
Results Among the 19 patients, 18 had become pregnant after being diagnosed with IBD, while one had developed UC newly after pregnancy. Throughout the gestation, all patients were treated with probiotics, 5-ASA, prednisolone, cytapheresis, or infliximab. The relapse rate during pregnancy was 21.7% (5/23 cases). The five patients who experienced a relapse were able to pursue their pregnancy after intensification of their treatments. There were no adverse fetal or neonatal problems, except in one case that required an emergency Caesarean section because of placental dysfunction and in which a very low-birth-weight infant was born preterm.
Conclusions Our present data confirmed that even if the disease flares up during pregnancy, good pregnancy outcomes can be achieved with an optimal intensification of the patient's treatment.
-
Citations
Citations to this article as recorded by- The pregnancy outcome and drug usage during pregnancy among Taiwanese inflammatory bowel disease patients
Chen‐Wang Chang, Shu‐Chen Wei, Jen‐Wei Chou, Tien‐Yu Huang, Chia‐Jung Kuo, Wen‐Hung Hsu, Chen‐Shuan Chung, Tzu‐Chi Hsu, Wei‐Chen Lin, Ming‐Jen Chen, Horng‐Yuan Wang
Advances in Digestive Medicine.2023; 10(4): 226. CrossRef - Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
Drugs.2020; 80(16): 1699. CrossRef
- The pregnancy outcome and drug usage during pregnancy among Taiwanese inflammatory bowel disease patients
- 5,630 View
- 79 Download
- 2 Web of Science
- 2 Crossref
Erratum
- Erratum: Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul
- Hiroshi Nakase, Bora Keum, Byong Duk Ye, Soo Jung Park, Hoon Sup Koo, Chang Soo Eun
- Intest Res 2016;14(4):381-381. Published online October 17, 2016
- DOI: https://doi.org/10.5217/ir.2016.14.4.381
-
PDFPubReader
-
Citations
Citations to this article as recorded by- Quality of Care in Inflammatory Bowel Disease: the Role of Steroid Assessment Tool (SAT) - a Review
Loredana GORAN, Monica STATE, Ana NEGREANU, Lucian NEGREANU
Medicina Moderna - Modern Medicine.2020; 27(3): 171. CrossRef
- Quality of Care in Inflammatory Bowel Disease: the Role of Steroid Assessment Tool (SAT) - a Review
- 4,273 View
- 44 Download
- 1 Crossref
Original Article
- Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul
- Hiroshi Nakase, Bora Keum, Byoung Duk Ye, Soo Jung Park, Hoon Sup Koo, Chang Soo Eun
- Intest Res 2016;14(3):231-239. Published online June 27, 2016
- DOI: https://doi.org/10.5217/ir.2016.14.3.231
-
Abstract
PDFPubReaderePub
<b>Background/Aims</b><br/> Inflammatory bowel disease (IBD) management guidelines have been released from Western countries, but no adequate data on the application of these guidelines in Asian countries and no surveys on the treatment of IBD in real practice exist. Since there is a growing need for a customized consensus for IBD treatment in Asian countries, Asian Organization of Crohn's and Colitis performed a multinational survey of medical doctors who treat IBD patients in Asian countries.
Methods A questionnaire was developed between August 2013 and November 2013. It was composed of 4 domains: personal information, IBD diagnosis, IBD treatment, and quality of IBD care. Upon completion of the questionnaire, a web-based survey was conducted between 17 March 2014 and 12 May 2014.
Results In total, 353 medical doctors treating IBD from ten Asian countries responded to the survey. This survey data suggested a difference in available medical treatments (budesonide, tacrolimus) among Asian countries. Therapeutic strategies regarding refractory IBD (acute severe ulcerative colitis [UC] refractory to intravenous steroids and refractory Crohn's disease [CD]) and active UC were coincident, however, induction therapies for mild to moderate inflammatory small bowel CD are different among Asian countries.
Conclusions This survey demonstrated that current therapeutic approaches and clinical management of IBD vary among Asian countries. Based on these results and discussions, we hope that optimal management guidelines for Asian IBD patients will be developed.
-
Citations
Citations to this article as recorded by- Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
Intestinal Research.2023; 21(3): 353. CrossRef - Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 523. CrossRef - Management and monitoring of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group: Surgical management,
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen Calixto Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 510. CrossRef - Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
Intestinal Research.2023; 21(3): 339. CrossRef - How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
Jihye Park
Intestinal Research.2023; 21(3): 275. CrossRef - Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia
Chenwen Cai, Juntao Lu, Lijie Lai, Dongjuan Song, Jun Shen, Jinlu Tong, Qing Zheng, Kaichun Wu, Jiaming Qian, Zhihua Ran
Intestinal Research.2022; 20(2): 213. CrossRef - Indications, Postoperative Management, and Long-term Prognosis of Crohn’s Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West
Jeanine H C Arkenbosch, Joyce W Y Mak, Jacky C L Ho, Evelien M J Beelen, Nicole S Erler, Frank Hoentjen, Alexander G L Bodelier, Gerard Dijkstra, Mariëlle Romberg-Camps, Nanne K H de Boer, Laurents P S Stassen, Andrea E van der Meulen, Rachel West, Oddeke
Inflammatory Bowel Diseases.2022; 28(Supplement): S16. CrossRef - UK Patients of Bangladeshi Descent with Crohn’s Disease Respond Less Well to TNF Antagonists Than Caucasian Patients
Radha Gadhok, Hannah Gordon, Gregory Sebepos-Rogers, Samantha Baillie, Saniath Akbar, Jane E. Abbott, Emma Michael, Omer F. Ahmad, Ben Cooper, James O. Lindsay
Digestive Diseases and Sciences.2020; 65(6): 1790. CrossRef - Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
Hiroshi Nakase
Gut and Liver.2020; 14(1): 7. CrossRef - Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study
Jesus K. Yamamoto-Furusho, Othman Al Harbi, Alessandro Armuzzi, Webber Chan, Enrique Ponce de Leon, Jiaming Qian, Marina Shapina, Murat Toruner, Chia-Hung Tu, Byong Duk Ye, Morgane Guennec, Cecilia Sison, Dirk Demuth, Olga Fadeeva, Qasim M. Rana Khan
Digestive and Liver Disease.2020; 52(8): 869. CrossRef - CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients
Yuki Yamamoto, Hiroshi Nakase, Minoru Matsuura, Shihoko Maruyama, Satohiro Masuda
International Journal of Molecular Sciences.2020; 21(12): 4347. CrossRef - Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia
Siew C Ng, Joyce Wing Yan Mak, Partha Pal, Rupa Banerjee
The Lancet Gastroenterology & Hepatology.2020; 5(12): 1089. CrossRef - Improving the quality of care for inflammatory bowel disease
Byong Duk Ye, Simon Travis
Intestinal Research.2019; 17(1): 45. CrossRef - Increased risk of atrial fibrillation in patients with inflammatory bowel disease: A nationwide population-based study
You-Jung Choi, Eue-Keun Choi, Kyung-Do Han, Jiesuck Park, Inki Moon, Euijae Lee, Won-Seok Choe, So-Ryoung Lee, Myung-Jin Cha, Woo-Hyun Lim, Seil Oh
World Journal of Gastroenterology.2019; 25(22): 2788. CrossRef - Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
Taku Kobayashi, Tadakazu Hisamatsu, Yasuo Suzuki, Haruhiko Ogata, Akira Andoh, Toshimitsu Araki, Ryota Hokari, Hideki Iijima, Hiroki Ikeuchi, Yoh Ishiguro, Shingo Kato, Reiko Kunisaki, Takayuki Matsumoto, Satoshi Motoya, Masakazu Nagahori, Shiro Nakamura,
Intestinal Research.2018; 16(2): 168. CrossRef - Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
Intestinal Research.2018; 16(3): 400. CrossRef - Computed Tomography and Magnetic Resonance Small Bowel Enterography
Seong Ho Park, Byong Duk Ye, Tae Young Lee, Joel G. Fletcher
Gastroenterology Clinics of North America.2018; 47(3): 475. CrossRef - Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome
Takahiko Toyonaga, Taku Kobayashi, Masaru Nakano, Eiko Saito, Satoko Umeda, Shinji Okabayashi, Ryo Ozaki, Toshifumi Hibi, Emiko Mizoguchi
PLOS ONE.2017; 12(9): e0185131. CrossRef - Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis
Meiying Zeng, Andong Shao, Hui Li, Yan Tang, Qiang Li, Zhiqian Guo, Chungen Wu, Yingsheng Cheng, He Tian, Wei-Hong Zhu
ACS Applied Materials & Interfaces.2017; 9(15): 13029. CrossRef - Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
Wei-Chen Lin, Jen-Wei Chou, Hsu-Heng Yen, Wen-Hung Hsu, Hung-Hsin Lin, Jen-Kou Lin, Chiao-Hsiung Chuang, Tien-Yu Huang, Horng-Yuan Wang, Shu-Chen Wei, Jau-Min Wong
Intestinal Research.2017; 15(4): 487. CrossRef - CT Enterography for Surveillance of Anastomotic Recurrence within 12 Months of Bowel Resection in Patients with Crohn's Disease: An Observational Study Using an 8-Year Registry
In Young Choi, Sang Hyoung Park, Seong Ho Park, Chang Sik Yu, Yong Sik Yoon, Jong Lyul Lee, Byong Duk Ye, Ah Young Kim, Suk-Kyun Yang
Korean Journal of Radiology.2017; 18(6): 906. CrossRef - Is Adsorptive Granulocyte and Monocyte Apheresis Effective as an Alternative Treatment Option in Patients with Ulcerative Colitis?
Seong Ran Jeon
Gut and Liver.2017; 11(2): 171. CrossRef - Cancer Risk in the Early Stages of Inflammatory Bowel Disease in Korean Patients: A Nationwide Population-based Study
Yoon Suk Jung, Minkyung Han, Sohee Park, Won Ho Kim, Jae Hee Cheon
Journal of Crohn's and Colitis.2017; 11(8): 954. CrossRef - Results of the first survey for the current status of inflammatory bowel disease management in Asian countries
Ji Won Kim
Intestinal Research.2016; 14(3): 199. CrossRef
- Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
- 7,173 View
- 106 Download
- 25 Web of Science
- 24 Crossref
Case Report
- Ischemic enteritis with intestinal stenosis
- Yorimitsu Koshikawa, Hiroshi Nakase, Minoru Matsuura, Takuya Yoshino, Yusuke Honzawa, Naoki Minami, Satoshi Yamada, Yumiko Yasuhara, Shigehiko Fujii, Toshihiro Kusaka, Dai Manaka, Hiroyuki Kokuryu
- Intest Res 2016;14(1):89-95. Published online January 26, 2016
- DOI: https://doi.org/10.5217/ir.2016.14.1.89
-
Abstract
PDFPubReaderePub
A 75-year-old man was admitted to our hospital with sudden onset of vomiting and abdominal distension. The patient was taking medication for arrhythmia. Computed tomography showed stenosis of the ileum and a small bowel dilatation on the oral side from the region of stenosis. A transnasal ileus tube was placed. Enteroclysis using contrast medium revealed an approximately 6-cm afferent tubular stenosis 10 cm from the terminal ileum and thumbprinting in the proximal bowel. Transanal double-balloon enteroscopy showed a circumferential shallow ulcer with a smooth margin and edema of the surrounding mucosa. The stenosis was so extensive that we could not perform endoscopic balloon dilation therapy. During hospitalization, the patient's nutritional status deteriorated. In response, we surgically resected the region of stenosis. Histologic examination revealed disappearance of the mucosal layer and transmural ulceration with marked fibrosis, especially in the submucosal layer. Hemosiderin staining revealed sideroferous cells in the submucosal layers. Based on the pathologic findings, the patient was diagnosed with ischemic enteritis. The patient's postoperative course was uneventful.
-
Citations
Citations to this article as recorded by- Myeloid Sarcoma in the Small Intestine
Masaya Iwamuro, Tomohiro Kamio, Shoichiro Hirata, Katsunori Matsueda, Daisuke Kametaka, Takehiro Tanaka, Seiji Kawano, Motoyuki Otsuka
Internal Medicine.2025;[Epub] CrossRef - Spontaneous multiple small bowel perforations due to ischemic enteritis: a case report
Cheru Lilay Gebrehiwet, Aklilu Yiheyis Abereha, Dawit Aysheshim Mulualem, Misgana Lemma Gurmu, Samuel Addisu Abera, Amanuel Kassa Tadesse, Girma Damtew Adisu, Ermias Teklehaimanot Yefter, Melaku Tessema kassie
BMC Geriatrics.2025;[Epub] CrossRef - Late Graft Failure Due to Arterio-Venous Fistula in the Free Jejunal Graft Mesentery Following Total Pharyngo-Laryngo-Esophagectomy for Cervical Esophageal Cancer: A Case Report
Koutarou Yamamoto, Tomoyuki Okumura, Takeshi Miwa, Yoshihisa Numata, Tatsuhiro Araki, Ayaka Itoh, Mina Fukasawa, Nana Kimura, Masakazu Nagamori, Kosuke Mori, Naoya Takeda, Tomohiro Minagawa, Kenta Sukegawa, Toru Watanabe, Katsuhisa Hirano, Isaya Hashimoto
Surgical Case Reports.2025; 11(1): n/a. CrossRef - Clinical characteristics and surgical management of ileal strictures caused by ischemic enteritis: a report of three cases
Yuya Kondo, Shingo Tsujinaka, Tomoya Miura, Yoh Kitamura, Yoshihiro Sato, Kentaro Sawada, Atsushi Mitamura, Toru Nakano, Yu Katayose, Chikashi Shibata
Journal of Surgical Case Reports.2025;[Epub] CrossRef - Smooth muscle degeneration of the mesenteric and branching veins causing ischemic enteritis: a case report
Taiki Sunakawa, Nobuo Ito, Ryo Moriyasu, Nobuya Seki, Daisuke Takeuchi, Kotaro Sasahara
Surgical Case Reports.2022;[Epub] CrossRef - Ischemic enteritis resulting from polycythemia vera
Soichi Yagi, Kiyohide Kioka, Yurina Koizumi, Takashi Nakai, Yasuko Kawasaki, Minako Tsutsumi, Naomi Ishii, Tomoaki Yamasaki, Hiroko Nebiki, Kiyoshi Maeda
Clinical Journal of Gastroenterology.2022; 15(5): 907. CrossRef - Association of decreased variation of coefficient R–R interval with ischemic colitis and small bowel obstruction
Toshio Arai, Hiroki Yamada, Takeya Edagawa, Satoshi Yoshida, Shigetoshi Hikimoto, Hiromichi Sougawa, Kenichiro Nakachi, Raffaele Serra
PLOS ONE.2020; 15(2): e0228117. CrossRef - Ileítis isquémica idiopática, con sangrado digestivo oscuro manifiesto
Gabriel Mosquera-Klinger, Reinaldo Andrés Rincón
Gastroenterología y Hepatología.2019; 42(7): 439. CrossRef - Small bowel strictures
Deniz Durmush, Arthur J. Kaffes
Current Opinion in Gastroenterology.2019; 35(3): 235. CrossRef - Ultrasonographic and histopathological features in 8 cats with fibrotic small intestinal stricture
Andrew Holloway, Mauro Pivetta, Roberta Rasotto
Veterinary Radiology & Ultrasound.2019; 60(4): 423. CrossRef - Experience with Balloon Dilatation in Crohn’s and Non-Crohn’s Benign Small-Bowel Strictures: Is There a Difference?
Akiyoshi Tsuboi, Shiro Oka, Shinji Tanaka, Sumio Iio, Ichiro Otani, Sayoko Kunihara, Ryohei Hayashi, Kazuaki Chayama
Gastroenterology Research and Practice.2019; 2019: 1. CrossRef - Idiopathic ischaemic ileitis, with overt obscure digestive bleeding
Gabriel Mosquera-Klinger, Reinaldo Andrés Rincón
Gastroenterología y Hepatología (English Edition).2019; 42(7): 439. CrossRef - Stenotic Ischemic Enteritis with Concomitant Hepatic Portal Venous Gas and Pneumatosis Cystoides Intestinalis
Naoto Iwai, Osamu Handa, Yuji Naito, Osamu Dohi, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiko Uchiyama, Takeshi Ishikawa, Tomohisa Takagi, Hideyuki Konishi, Yoshito Itoh
Internal Medicine.2018; 57(14): 1995. CrossRef - Etiology and long‐term rebleeding of endoscopic ulcerative lesions in the small bowel in patients with obscure gastrointestinal bleeding: A multicenter cohort study
Tomonori Aoki, Atsuo Yamada, Yoshihiro Hirata, Hirobumi Suzuki, Ayako Nakada, Ryota Niikura, Motoko Seto, Makoto Okamoto, Kazuhiko Koike
Journal of Gastroenterology and Hepatology.2018; 33(7): 1327. CrossRef
- Myeloid Sarcoma in the Small Intestine
- 8,547 View
- 58 Download
- 12 Web of Science
- 14 Crossref
Original Articles
- Efficacy of Thiopurines in Biologic-Naive Japanese Patients With Crohn's Disease: A Single-Center Experience
- Takuya Yoshino, Minoru Matsuura, Naoki Minami, Satoshi Yamada, Yusuke Honzawa, Masamichi Kimura, Yorimitsu Koshikawa, Ali Madian, Takahiko Toyonaga, Hiroshi Nakase
- Intest Res 2015;13(3):266-273. Published online June 9, 2015
- DOI: https://doi.org/10.5217/ir.2015.13.3.266
-
Abstract
PDFPubReader
<b>Background/Aims</b><br/> Early use of biologics in patients with Crohn's disease (CD) improves quality of life. However, the effects of the early use of immunomodulators on long-term outcomes remain unclear. This study aimed to evaluate the effects of immunomodulators in patients with CD.
Methods Between January 2004 and December 2011, 47 biologic-naive CD patients treated with thiopurines alone for remission maintenance were analyzed. The patients were classified into 2 groups depending on the presence or absence of digestive complications. We evaluated the efficacy of and predictive factors for thiopurine use for remission maintenance.
Results The cumulative relapse rates at 24 and 60 months were 13.7% and 35.4%, respectively. Regarding patient characteristics, there was a significant difference in patient history of surgery between the non-relapse and relapse groups (
P =0.021). The cumulative relapse rate was lower in patients without a history of surgery than in those with such a history (27.2% and 52.9% at 60.0 months, respectively). Multivariate analysis suggested that the prevalence of stricturing and penetrating complications is an independent factor for relapse. The cumulative relapse rate in patients without a history of surgery was significantly lower in the non-stricturing and non-penetrating group than in the stricturing and penetrating group (11.8% at 85.0 months vs. 58.5% at 69.0 months;P =0.036).Conclusions Thiopurine use might be beneficial for the long-term maintenance of remission in biologic-naive Crohn's disease patients without digestive complications and a history of surgery.
-
Citations
Citations to this article as recorded by- Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis
Mukesh Kumar Ranjan, Peeyush Kumar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Sandeep K Mundhra, Rithvik Golla, Shubi Virmani, Raju Sharma, Peush Sahni, Prasenjit Das, Mani Kalaivani, Ashish Datt Upadhyay, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Journal of Crohn's and Colitis.2024; 18(2): 192. CrossRef - Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review
Julien D Schulberg, Emily K Wright, Bronte A Holt, Helen E Wilding, Amy L Hamilton, Alyson L Ross, Michael A Kamm
Journal of Gastroenterology and Hepatology.2021; 36(2): 344. CrossRef - Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study
Hee Seung Hong, Kyuwon Kim, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef - NUDT15,FTO, andRUNX1genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
Toshiyuki Sato, Tetsuya Takagawa, Yoichi Kakuta, Akihiro Nishio, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Yuko Kita, Takako Miyazaki, Masaki Iimuro, Nobuyuki Hida, Kazutoshi Hori, Hiroki Ikeuchi, Shiro Nakamura
Intestinal Research.2017; 15(3): 328. CrossRef - Importance of Patients’ Knowledge of Their Prescribed Medication in Improving Treatment Adherence in Inflammatory Bowel Disease
Chung Hyun Tae, Sung-Ae Jung, Hye Sung Moon, Jung-A Seo, Hye Kyung Song, Chang Mo Moon, Seong-Eun Kim, Ki-Nam Shim, Hye-Kyung Jung
Journal of Clinical Gastroenterology.2016; 50(2): 157. CrossRef
- Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis
- 5,487 View
- 47 Download
- 5 Web of Science
- 5 Crossref
- Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis
- Satoshi Yamada, Takuya Yoshino, Minoru Matsuura, Masamichi Kimura, Yorimitsu Koshikawa, Naoki Minami, Takahiko Toyonaga, Yusuke Honzawa, Hiroshi Nakase
- Intest Res 2015;13(3):250-258. Published online June 9, 2015
- DOI: https://doi.org/10.5217/ir.2015.13.3.250
-
Abstract
PDFSupplementary MaterialPubReader
<b>Background/Aims</b><br/> The long-term clinical outcomes of patients with bio-naive ulcerative colitis (UC) who maintain remission with thiopurine are unclear. The aim of this study was to assess the long-term efficacy and safety of maintenance treatment with thiopurine in UC patients.
Methods This was a retrospective observational cohort analysis conducted at a single center. Between December 1998 and August 2013, 59 of 87 patients with bio-naive UC who achieved remission after induction with treatments other than biologics were enrolled. Remission maintenance with thiopurine was defined as no concomitant treatment needed other than 5-aminosalicylate without relapse. We assessed the remission-maintenance rate, mucosal healing rate, colectomy-free rate, and treatment safety in UC patients who received thiopurine as maintenance treatment.
Results The 84-month cumulative remission-maintenance and colectomy-free survival rates in the UC patients who were receiving maintenance treatment with thiopurine and 5-aminosalicylate were 43.9% and 88.0%, respectively. Of the 38 patients who underwent colonoscopy during thiopurine maintenance treatment, 23 (60.5%) achieved mucosal healing. Of the 59 patients who achieved clinical remission with thiopurine, 6 patients (10.2%) discontinued the thiopurine therapy because of adverse events.
Conclusions Our study demonstrates the long-term efficacy and safety of thiopurine treatment in patients with bio-naive UC.
-
Citations
Citations to this article as recorded by- Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis
Mukesh Kumar Ranjan, Peeyush Kumar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Sandeep K Mundhra, Rithvik Golla, Shubi Virmani, Raju Sharma, Peush Sahni, Prasenjit Das, Mani Kalaivani, Ashish Datt Upadhyay, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Journal of Crohn's and Colitis.2024; 18(2): 192. CrossRef - Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
Makoto Naganuma, Kenji Watanabe, Satoshi Motoya, Haruhiko Ogata, Toshiyuki Matsui, Yasuo Suzuki, Lyann Ursos, Shigeru Sakamoto, Mitsuhiro Shikamura, Tetsuharu Hori, Jovelle Fernandez, Mamoru Watanabe, Toshifumi Hibi, Takanori Kanai
Journal of Gastroenterology and Hepatology.2022; 37(1): 81. CrossRef - Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
Satohiro Matsumoto, Hirosato Mashima
Crohn's & Colitis 360.2021;[Epub] CrossRef - Treatment of Inflammatory Bowel Disease: A Comprehensive Review
Zhaobei Cai, Shu Wang, Jiannan Li
Frontiers in Medicine.2021;[Epub] CrossRef - Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
Hiroshi Nakase
Gut and Liver.2020; 14(1): 7. CrossRef - The Leading Edge of the Treatment of Inflammatory Bowel Disease
Hiroshi Nakase
Nihon Naika Gakkai Zasshi.2020; 109(6): 1145. CrossRef -
Predictive Role of
NUDT15
Variants on Thiopurine-Induced Myelotoxicity in Asian Inflammatory Bowel Disease Patients
Natalia Sutiman, Sylvia Chen, Khoon Lin Ling, Sai Wei Chuah, Wai Fook Leong, Vinayak Nadiger, Madeline Tjai, Chris San Choon Kong, Brian John Schwender, Webber Chan, Hang Hock Shim, Wee Chian Lim, Chiea Chuen Khor, Yin Bun Cheung, Balram Chowbay
Pharmacogenomics.2018; 19(1): 31. CrossRef - NUDT15,FTO, andRUNX1genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
Toshiyuki Sato, Tetsuya Takagawa, Yoichi Kakuta, Akihiro Nishio, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Yuko Kita, Takako Miyazaki, Masaki Iimuro, Nobuyuki Hida, Kazutoshi Hori, Hiroki Ikeuchi, Shiro Nakamura
Intestinal Research.2017; 15(3): 328. CrossRef - Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis
Yoon Jee Lee, Jae Hee Cheon, Jae Hyun Kim, SunHo Yoo, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim
Yonsei Medical Journal.2017; 58(1): 144. CrossRef - Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study
Caroline Prieux-Klotz, Stéphane Nahon, Aurelien Amiot, Leila Sinayoko, Carole Galéano-Cassaz, Stanislas Chaussade, Romain Coriat, Pierre Lahmek, Vered Abitbol
Digestive Diseases and Sciences.2017; 62(2): 473. CrossRef - Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission
Jae Hyun Kim, Jae Hee Cheon, Yehyun Park, Hyun Jung Lee, Soo Jung Park, Tae Il Kim, Won Ho Kim
Scandinavian Journal of Gastroenterology.2016; 51(9): 1069. CrossRef - Is Long-Term Therapy With Thiopurines Effective for Maintaining Remission in Patients With Moderate-To-Severe Ulcerative Colitis?
Seong Ran Jeon, Won Ho Kim
Intestinal Research.2015; 13(3): 191. CrossRef
- Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis
- 6,314 View
- 62 Download
- 12 Web of Science
- 12 Crossref
Case Report
- Usefulness of Adalimumab for Treating a Case of Intestinal Behçet's Disease With Trisomy 8 Myelodysplastic Syndrome
- Masamichi Kimura, Yoshihisa Tsuji, Masako Iwai, Masahiro Inagaki, Ali Madian, Takuya Yoshino, Minoru Matsuura, Hiroshi Nakase
- Intest Res 2015;13(2):166-169. Published online April 27, 2015
- DOI: https://doi.org/10.5217/ir.2015.13.2.166
-
Abstract
PDFPubReader
Behçet's disease (BD) is a systemic vasculitis, while myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematologic disorders characterized by ineffective hematopoiesis. Some studies suggest a relationship between MDS and BD, especially intestinal BD, and trisomy 8 seems to play an important role in both diseases. There are several reports on patients with BD comorbid with MDS involving trisomy 8 that frequently have intestinal lesions refractory to conventional medical therapies. Tumor necrosis factor (TNF)-α is strongly involved in the pathophysiology of several autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and BD. In addition, TNF-α plays an important role in the pathophysiology of MDS by inhibiting normal hematopoiesis and inducing the programmed cell death of normal total bone marrow cells and normal CD34+ cells. Recent clinical reports demonstrate the favorable effect of TNF-α antagonists in patients with refractory intestinal BD and in those with MDS. We present the case of a patient with intestinal BD and MDS involving trisomy 8 who was successfully treated with adalimumab.
-
Citations
Citations to this article as recorded by- The Expanding Spectrum of Autoinflammatory Diseases
Kiyoshi Migita, Yuya Fujita, Tomoyuki Asano, Shuzo Sato
Internal Medicine.2023; 62(1): 43. CrossRef - Refractory Intestinal Behçet-Like Disease Associated with Trisomy 8 Myelodysplastic Syndrome Resolved by Parenteral Nutrition
Ryo Takahashi, Yasuo Matsubara, Satoshi Takahashi, Kazuaki Yokoyama, Lim Lay Ahyoung, Michiko Koga, Hiroyuki Sakamoto, Narikazu Boku, Dai Shida, Hiroshi Yotsuyanagi
Case Reports in Gastroenterology.2023; 17(1): 287. CrossRef - The Expanding Spectrum of Autoinflammatory Diseases
Kiyoshi Migita, Yuya Fujita, Tomoyuki Asano, Shuzo Sato
Internal Medicine.2022;[Epub] CrossRef - CAISC: A software to integrate copy number variations and single nucleotide mutations for genetic heterogeneity profiling and subclone detection by single-cell RNA sequencing
Jeerthi Kannan, Liza Mathews, Zhijie Wu, Neal S. Young, Shouguo Gao
BMC Bioinformatics.2022;[Epub] CrossRef - Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications
Claudio Fozza, Andrea Murtas, Giovanni Caocci, Giorgio La Nasa
Leukemia Research.2022; 117: 106856. CrossRef - Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
Jae Hee Cheon
Journal of Rheumatic Diseases.2021; 28(1): 4. CrossRef - Syndrome de pseudo-Behçet et autres manifestations dysimmunitaires associées aux syndromes myélodysplasiques avec trisomie 8
N. Wesner, P. Fenaux, V. Jachiet, L. Ades, O. Fain, A. Mekinian
La Revue de Médecine Interne.2021; 42(3): 170. CrossRef - The Clinical Features of Intestinal Disease in Myelodysplastic Syndromes with Trisomy 8
Yusuke Honzawa
Nippon Daicho Komonbyo Gakkai Zasshi.2021; 74(10): 594. CrossRef - Update on the Treatment of Behcet’s Disease of the Small Bowel with Biologic Agents
Yehyun Park, Jae Hee Cheon
Current Gastroenterology Reports.2020;[Epub] CrossRef - How to treat myelodysplastic syndrome with clinical features resembling Behçet syndrome: a case-based systematic review
Umut Yilmaz, Muhlis Cem Ar, Sinem Nihal Esatoglu, Isil Bavunoglu, Yusuf Ziya Erzin, Ali Ibrahim Hatemi, Suleyman Yildirim, Gülen Hatemi, Aykut Ferhat Celik
Annals of Hematology.2020; 99(6): 1193. CrossRef - Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet’s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants
Kenji Watanabe, Satoshi Tanida, Nagamu Inoue, Reiko Kunisaki, Kiyonori Kobayashi, Masakazu Nagahori, Katsuhiro Arai, Motoi Uchino, Kazutaka Koganei, Taku Kobayashi, Mitsuhiro Takeno, Fumiaki Ueno, Takayuki Matsumoto, Nobuhisa Mizuki, Yasuo Suzuki, Tadakaz
Journal of Gastroenterology.2020; 55(7): 679. CrossRef - Sonic hedgehog signaling pathway in Myelodysplastic Syndrome: Abnormal activation and jervine intervention
YuTing Qin, Ming Jiang, Nilupar Tuerxung, Huan Wang, Fang Zhao, Yin Zhen, Jianping Hao
Gene.2020; 754: 144881. CrossRef - Gastrointestinal Behcet’s-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review
Nadege Wesner, Louis Drevon, Alexis Guedon, Jean Baptiste Fraison, Benjamin Terrier, Salim Trad, Jean Emmanuel Kahn, Achille Aouba, Jerome Gillard, Matthieu Ponsoye, Thomas Hanslik, Clement Gourguechon, Eric Liozon, Kamel Laribi, Julien Rossignol, Olivier
Leukemia & Lymphoma.2019; 60(7): 1782. CrossRef - Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease
Masashi Kono, Toshiharu Sakurai, Kazuki Okamoto, Tomoyuki Nagai, Yoriaki Komeda, Hiroshi Kashida, Kosuke Minaga, Ken Kamata, Mamoru Takenaka, Satoru Hagiwara, Tomohiro Watanabe, Naoshi Nishida, Eisuke Enoki, Hiroaki Inoue, Itaru Matsumura, Masatoshi Kudo
Internal Medicine.2019; 58(14): 2029. CrossRef - Intestinal Behçet disease associated with myelodysplastic syndrome accompanying trisomy 8 successfully treated with abdominal surgery followed by hematopoietic stem cell transplantation
Tomoyuki Asano, Shuzo Sato, Makiko Yashiro Furuya, Hiroshi Takahashi, Akiko Shichishima-Nakamura, Hiroshi Ohkawara, Tatsuo Fujiwara, Naohiko Gunji, Choichiro Hashimoto, Tomoyuki Momma, Motonobu Saito, Hiroshi Nakano, Guy Watanabe, Jumpei Temmoku, Yuya Fuj
Medicine.2019; 98(46): e17979. CrossRef - Long-term maintenance of the mucosal healing induced by azacitidine therapy in a patient with intestinal Behçet’s-like disease accompanied with myelodysplastic syndrome involving trisomy 8
Nahoko Tanaka, Hirotake Sakuraba, Hiroto Hiraga, Ko Mayama, Hidezumi Kikuchi, Dai Kishida, Yui Akemoto, Keisuke Hasui, Shinji Ota, Rina Watanabe, Yasuhisa Murai, Takato Maeda, Kosuke Kamata, Tetsuya Tatsuta, Manabu Sawaya, Daisuke Chinda, Tatsuya Mikami,
Immunological Medicine.2019; 42(3): 135. CrossRef - Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef - High Incidence of Gastrointestinal Ulceration and Cytogenetic Aberration of Trisomy 8 as Typical Features of Behçet’s Disease Associated with Myelodysplastic Syndrome: A Series of 16 Consecutive Chinese Patients from the Shanghai Behçet’s Disease Database
Yan Shen, Hai-Fen Ma, Dan Luo, Jian-Fei Cai, Jun Zou, Jian-Long Guan
BioMed Research International.2018; 2018: 1. CrossRef - Anti-Tumor Necrosis Factor Therapy in Intestinal Beh Ccedil;et rsquo;s Disease
Jihye Park, Jae Hee Cheon
Gut and Liver.2018; 12(6): 623. CrossRef - Update on the Medical Management of Gastrointestinal Behçet’s Disease
Giuseppe Lopalco, Donato Rigante, Vincenzo Venerito, Claudia Fabiani, Rossella Franceschini, Michele Barone, Giovanni Lapadula, Mauro Galeazzi, Bruno Frediani, Florenzo Iannone, Luca Cantarini
Mediators of Inflammation.2017; 2017: 1. CrossRef - Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behçet’s disease
Jihye Park, Jae Hee Cheon, Yong Eun Park, Yoon Jee Lee, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim
International Journal of Colorectal Disease.2017; 32(5): 745. CrossRef - 18F-FDG PET/CT Findings in Two Cases With Myelodysplastic Syndrome Accompanied by Behçet’s Disease
Kimiteru Ito, Kazuo Kubota
Clinical Nuclear Medicine.2016; 41(8): e392. CrossRef - Multiple colonic ulcers associated with trisomy 8: serial changes in colonoscopic findings
Shunichi Yanai, Shotaro Nakamura, Keisuke Kawasaki, Shigeki Ito, Tamotsu Sugai, Takayuki Matsumoto
Clinical Journal of Gastroenterology.2016; 9(5): 298. CrossRef - Acute Monocytic Leukemia Masquerading Behçet’s Disease-Like Illness at Onset in an Elderly Female
Shigeru Koba, Toshio Sekioka, Sorou Takeda, Aya Miyagawa-Hayashino, Keisuke Nishimura, Shinsaku Imashuku
Case Reports in Hematology.2016; 2016: 1. CrossRef
- The Expanding Spectrum of Autoinflammatory Diseases
- 10,172 View
- 86 Download
- 23 Web of Science
- 24 Crossref
Reviews
- Diagnosis and Treatment of Ulcerative Colitis with Cytomegalovirus Infection: Importance of Controlling Mucosal Inflammation to Prevent Cytomegalovirus Reactivation
- Hiroshi Nakase, Yusuke Honzawa, Takahiko Toyonaga, Satoshi Yamada, Naoki Minami, Takuya Yoshino, Minoru Matsuura
- Intest Res 2014;12(1):5-11. Published online January 28, 2014
- DOI: https://doi.org/10.5217/ir.2014.12.1.5
-
Abstract
PDFPubReader
Human cytomegalovirus (HCMV) is a member of the herpesvirus family. HCMV infection persists throughout the host lifespan in a latent state following primary infection. The ability of HCMV to escape control by the host immune system and its resulting reactivation suggests the importance of ongoing immune surveillance in the prevention of HCMV reactivation. HCMV is a common cause of opportunistic infection that causes severe and fatal disease in immune-compromised individuals. In inflammatory bowel disease patients, particularly those with ulcerative colitis (UC), HCMV is often reactivated because these patients are frequently treated with immunosuppressive agents. This reactivation exacerbates colitis. Additionally, HCMV infection can induce severe colitis, even in patients with UC who have never been treated with immunosuppressive agents. However, the role of HCMV in colonic inflammation in patients with UC remains unclear. Here, we present previous and current clinical data on the diagnosis and treatment of HCMV infection in UC. Additionally, our experimental data from a newly established mouse model mimicking UC with concomitant CMV infection clearly demonstrate that inflammation could result in the exacerbation of UC disease activity with induction of HCMV reactivation. In summary, optimal control of colonic inflammation should be achieved in UC patients who are refractory to conventional immunosuppressive therapies and are positive for HCMV.
-
Citations
Citations to this article as recorded by- Predictive Factors of Cytomegalovirus Colonic Reactivation in Patients with Active Ulcerative Colitis
Alexandre Jentzer, Aymeric Cantais, Xavier Roblin, Mathilde Barrau, Arnauld Garcin, Thomas Bourlet, Bruno Pozzetto, Sylvie Pillet
Viruses.2025; 17(4): 555. CrossRef - A case of ulcerative colitis in a patient undergoing surgery due to exacerbation resulting in toxic megacolon after SARS-CoV-2 vaccination
Ryota Ogihara, Minoru Matsuura, Takuya Ishida, Hiromu Morikubo, Tatsuya Mitsui, Daisuke Saito, Jun Miyoshi, Junji Shibahara, Eiji Sunami, Tadakazu Hisamatsu
Clinical Journal of Gastroenterology.2025;[Epub] CrossRef - Impact of cytomegalovirus on outcomes in acute severe ulcerative colitis: a retrospective observational study
Dazhong Huang, Michael Rennie, Alicia Krasovec, Shyam Nagubandi, Sichang Liu, Edward Ge, Barinder Khehra, Michael Au, Shobini Sivagnanam, Vu Kwan, Claudia Rogge, Nikola Mitrev, Viraj Kariyawasam
Therapeutic Advances in Chronic Disease.2024;[Epub] CrossRef - Cytomegalovirus in Ulcerative Colitis: An Unwanted “Guest”
Danusia Onisor, Olga Brusnic, Simona Mocan, Mircea Stoian, Calin Avram, Adrian Boicean, Daniela Dobru
Pathogens.2024; 13(8): 650. CrossRef - The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection
Tsukasa Yamawaka, Hiroki Kitamoto, Masanori Nojima, Tomoe Kazama, Kohei Wagatsuma, Keisuke Ishigami, Shuji Yamamoto, Yusuke Honzawa, Minoru Matsuura, Hiroshi Seno, Hiroshi Nakase
Journal of Gastroenterology.2023; 58(1): 44. CrossRef - Microscopic observations of sites and forms of ettringite in the microstructure of deteriorated concrete
Y. Ando, H. Shinichi, T. Katayama, K. Torii
Materiales de Construcción.2022; 72(346): e283. CrossRef - Ulcerative Colitis and Its Association with Cytomegalovirus
梦鸽 李
Advances in Clinical Medicine.2022; 12(06): 5506. CrossRef - Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study
Hong Yang, Zhihua Ran, Meng Jin, Jia-Ming Qian
Gut and Liver.2022; 16(5): 726. CrossRef - Impact of Dextran-Sodium-Sulfate-Induced Enteritis on Murine Cytomegalovirus Reactivation
Alexandre Jentzer, Sébastien Fauteux-Daniel, Paul Verhoeven, Aymeric Cantais, Melyssa Yaugel Novoa, Fabienne Jospin, Blandine Chanut, Nicolas Rochereau, Thomas Bourlet, Xavier Roblin, Bruno Pozzetto, Sylvie Pillet
Viruses.2022; 14(12): 2595. CrossRef - Human Cytomegalovirus and Autoimmune Diseases: Where Are We?
Francesca Gugliesi, Selina Pasquero, Gloria Griffante, Sara Scutera, Camilla Albano, Sergio Fernando Castillo Pacheco, Giuseppe Riva, Valentina Dell’Oste, Matteo Biolatti
Viruses.2021; 13(2): 260. CrossRef - Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission
Jongbeom Shin, Sung Min Kong, Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim
Gut and Liver.2021; 15(3): 401. CrossRef - Clinical characteristics of cytomegalovirus gastritis
Dan Chen, Ruijie Zhao, Wei Cao, Weixun Zhou, Ying Jiang, Shangzhu Zhang, Yang Chen, Guijun Fei, Ji Li, Jiaming Qian
Medicine.2020; 99(5): e18927. CrossRef - Current Diagnostic and Therapeutic Approaches to Cytomegalovirus Infections in Ulcerative Colitis Patients Based on Clinical and Basic Research Data
Yoshihiro Yokoyama, Tsukasa Yamakawa, Takehiro Hirano, Tomoe Kazama, Daisuke Hirayama, Kohei Wagatsuma, Hiroshi Nakase
International Journal of Molecular Sciences.2020; 21(7): 2438. CrossRef - Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC)
Alexandre Jentzer, Pauline Veyrard, Xavier Roblin, Pierre Saint-Sardos, Nicolas Rochereau, Stéphane Paul, Thomas Bourlet, Bruno Pozzetto, Sylvie Pillet
Microorganisms.2020; 8(7): 1078. CrossRef - Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis
Yoki Furuta, Hideaki Miyamoto, Hideaki Naoe, Miki Shimoda, Yukari Hinokuma, Tomohiro Miyamura, Azusa Miyashita, Satoshi Fukushima, Motohiko Tanaka, Yutaka Sasaki
Case Reports in Gastroenterology.2020; 14(1): 103. CrossRef - Exacerbation causes among inflammatory bowel disease patients in Guilan Province north of Iran
Raheleh Sadat Hosseini, Fariborz Mansour-Ghanaei, Afshin Shafaghi, Amineh Hojati, Farahnaz Joukar, Zahra Atrkar Roushan, Fakhri Alsadat Hosseini, Sara Mavaddati
Journal of Coloproctology.2019; 39(02): 138. CrossRef - Management of elderly ulcerative colitis in Japan
Masaaki Higashiyama, Akira Sugita, Kazutaka Koganei, Kenji Wanatabe, Yoko Yokoyama, Motoi Uchino, Masakazu Nagahori, Makoto Naganuma, Shigeki Bamba, Shingo Kato, Ken Takeuchi, Teppei Omori, Tomohisa Takagi, Satohiro Matsumoto, Mitsuo Nagasaka, Shintaro Sa
Journal of Gastroenterology.2019; 54(7): 571. CrossRef - Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)
Intestinal Research.2018; 16(2): 178. CrossRef - Cytomegalovirus infection in ulcerative colitis assessed by quantitative polymerase chain reaction: risk factors and effects of immunosuppressants
Yujiro Henmi, Kazuki Kakimoto, Takuya Inoue, Kei Nakazawa, Minori Kubota, Azusa Hara, Takashi Mikami, Yutaka Naka, Yuki Hirata, Yoshimasa Hirata, Taisuke Sakanaka, Sadaharu Nouda, Toshihiko Okada, Ken Kawakami, Toshihisa Takeuchi, Kazunari Tominaga, Kazuh
Journal of Clinical Biochemistry and Nutrition.2018; 63(3): 246. CrossRef - Treatment of inflammatory bowel disease by leukocytapheresis
Emre Gerçeker, Hakan Yüceyar, Elmas Kasap, Ufuk Demirci, Burcu Ceren Ekti, İsmet Aydoğdu, Mine Miskioğlu
Transfusion and Apheresis Science.2017; 56(3): 421. CrossRef - Targeting cytomegalovirus during ulcerative colitis flare-ups
Hiroshi Nakase, Kei Onodera
Expert Review of Gastroenterology & Hepatology.2016; 10(10): 1119. CrossRef - Natural History of Elderly-onset Ulcerative Colitis: Results from a Territory-wide Inflammatory Bowel Disease Registry
Hai Yun Shi, Francis K. L. Chan, Wai Keung Leung, Michael K. K. Li, Chi Man Leung, Shun Fung Sze, Jessica Y. L. Ching, Fu Hang Lo, Steve W. C. Tsang, Edwin H. S. Shan, Lai Yee Mak, Belsy C. Y. Lam, Aric J. Hui, Sai Ho Wong, Marc T. L. Wong, Ivan F. N. Hun
Journal of Crohn's and Colitis.2016; 10(2): 176. CrossRef - Cytomegalovirus in inflammatory bowel disease: A systematic review
Tessa EH Römkens
World Journal of Gastroenterology.2016; 22(3): 1321. CrossRef - Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2ndAsian Organization of Crohn's and Colitis (AOCC) meeting in Seoul
Hiroshi Nakase, Bora Keum, Byoung Duk Ye, Soo Jung Park, Hoon Sup Koo, Chang Soo Eun
Intestinal Research.2016; 14(3): 231. CrossRef - Risk Factors and Clinical Outcomes Associated with Cytomegalovirus Colitis in Patients with Acute Severe Ulcerative Colitis
Ho-Su Lee, Sang Hyoung Park, Sung-Han Kim, Jihun Kim, Jene Choi, Hyo Jeong Lee, Wan Soo Kim, Jeong-Mi Lee, Min Seob Kwak, Sung Wook Hwang, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Ki
Inflammatory Bowel Diseases.2016; 22(4): 912. CrossRef - Human cytomegalovirus encoded chemokine receptor US28 activates the HIF-1α/PKM2 axis in glioblastoma cells
Raymond H. de Wit, Azra Mujić-Delić, Jeffrey R. van Senten, Alberto Fraile-Ramos, Marco Siderius, Martine J. Smit
Oncotarget.2016; 7(42): 67966. CrossRef - Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences
Hiroshi Nakase, Hans Herfarth
Inflammatory Intestinal Diseases.2016; 1(1): 15. CrossRef - Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis
Sylvie Pillet, Camille Jarlot, Mathilde Courault, Emilie Del Tedesco, Renaud Chardon, Pierre Saint-Sardos, Emilie Presles, Jean-Marc Phelip, Philippe Berthelot, Bruno Pozzetto, Xavier Roblin
Inflammatory Bowel Diseases.2015; 21(7): 1580. CrossRef - Evaluation of a multiplex PCR assay for detection of cytomegalovirus in stool samples from patients with ulcerative colitis
Saifun Nahar
World Journal of Gastroenterology.2015; 21(44): 12667. CrossRef - Author's Reply
Jaeyoung Chun, Jong Pil Im
Intestinal Research.2015; 13(2): 184. CrossRef - Reply: Careful Assessment Is Needed in Patients with Ulcerative Colitis with Evidence of Cytomegalovirus Reactivation
You Sun Kim, Joo Sung Kim
Gut and Liver.2015; 9(2): 254. CrossRef - Usefulness of the Cytomegalovirus Antigenemia Assay in Patients With Ulcerative Colitis
Jaeyoung Chun, Changhyun Lee, Ji-eun Kwon, Sung Wook Hwang, Sang Gyun Kim, Joo Sung Kim, Hyun Chae Jung, Jong Pil Im
Intestinal Research.2015; 13(1): 50. CrossRef - Long-Term Outcomes of Cytomegalovirus Reactivation in Patients with Moderate to Severe Ulcerative Colitis: A Multicenter Study
You Sun Kim, Young-Ho Kim, Joo Sung Kim, Seong Yeon Jeong, Soo Jeong Park, Jae Hee Cheon, Byong Duk Ye, Sung-Ae Jung, Young Sook Park, Chang Hwan Choi, Kyeung Ok Kim, Byung Ik Jang, Dong Soo Han, Suk-Kyun Yang, Won Ho Kim
Gut and Liver.2014; 8(6): 643. CrossRef
- Predictive Factors of Cytomegalovirus Colonic Reactivation in Patients with Active Ulcerative Colitis
- 7,524 View
- 89 Download
- 32 Web of Science
- 33 Crossref
- Role of the CXC12-CXCR4 Axis and CXCL16 in Inflammatory Bowel Disease
- Hiroshi Nakase, Minoru Matsuura, Sakae Mikami, Norimitsu Uza, Tsutomu Chiba
- Intest Res 2012;10(2):125-133. Published online April 30, 2012
- DOI: https://doi.org/10.5217/ir.2012.10.2.125
-
Abstract
PDF
- Numerous studies of colitis in IBD (inflammatory bowel diseases) patients and in animal models have demonstrated that both inflammatory cytokines and chemokines are up-regulated in settings of active inflammation. Blockade or absence of various cytokines and chemokines attenuates the disease in murine models of IBD. Therefore, identifying cytokines and chemokines involved in intestinal inflammation provide promising targets for the development of new drugs in the treatment of IBD. In general, chemokines have been implicated in many fundamental immune processes including lymphoid organogenesis, immune cell differentiation, development and positioning. Many chemokines are markedly increased in intestinal tissue from patients with IBD. In this study, we focused on the role of CXCL12-CXCR4 and CXCL16. CXCL12-CXCR4 axis plays a crucial role in the pathophysiology of IBD, especially UC, while SR-PSOX/CXCL16 plays a significant role in the pathophysiology of CD. Our present data suggest new insights into the etiology of IBD and we hope that the manipulation of these chemokines may have therapeutic value. (Intest Res 2012;10:125-133)
-
Citations
Citations to this article as recorded by- The ERβ‐CXCL19/CXCR4‐NFκB pathway is critical in mediating the E2-induced inflammation response in the orange-spotted grouper (Epinephelus coioides)
Qing Wang, Fengqi Huang, Xuzhuo Duan, Huitao Cheng, Chunli Zhang, Lihua Li, Xinhe Ruan, Qi He, Wenbiao Niu, Huirong Yang, Danqi Lu, Leyun Zheng, Huihong Zhao
The Journal of Steroid Biochemistry and Molecular Biology.2021; 212: 105926. CrossRef - The CXC chemokines and CXC chemokine receptors in orange-spotted grouper (Epinephelus coioides) and their expression after Singapore grouper iridovirus infection
Qing Wang, Shaowen Wang, Yong Zhang, Yepin Yu, Huihong Zhao, Huirong Yang, Leyun Zheng, Min Yang, Qiwei Qin
Developmental & Comparative Immunology.2019; 90: 10. CrossRef - Mesenchymal stem cells and CXC chemokine receptor 4 overexpression improved the therapeutic effect on colitis via mucosa repair
Zheng Chen, Qianqian Chen, Haitao Du, Lijuan Xu, Jun Wan
Experimental and Therapeutic Medicine.2018;[Epub] CrossRef - Association ofNOD1,CXCL16,STAT6andTLR4gene polymorphisms with Malaysian patients with Crohn’s disease
Kek Heng Chua, Jin Guan Ng, Ching Ching Ng, Ida Hilmi, Khean Lee Goh, Boon Pin Kee
PeerJ.2016; 4: e1843. CrossRef
- The ERβ‐CXCL19/CXCR4‐NFκB pathway is critical in mediating the E2-induced inflammation response in the orange-spotted grouper (Epinephelus coioides)
- 3,341 View
- 32 Download
- 4 Crossref
First
Prev
